SCP Foundation Secure, Contain, Protect About About Us Site Rules FAQ Licensing Criticism Policy Article Deletions Community Site News IRC Chat Authors' Pages Artist Directory Contest Archive Staff List Resources Guides Essays & Resources Wiki Syntax Sandbox Usertools Sister Sites SCP International Wanderer's Library Contact Us ≡ About About Us Site Rules FAQ Licensing Criticism Policy Article Deletions Contact Staff Community Site News IRC Chat Authors' Pages Artist Directory Contest Archive Staff List Resources Guides Search this site Search • ◦ ◦ ◦ ◦ ◦ ◦ • ◦ ◦ ◦ ◦ ◦ ◦ • ◦ ◦ ◦ ◦ ◦ • ◦ ◦ • • ◦ ◦ ◦ ◦ ◦ ◦ ◦ • ◦ ◦ ◦ ◦ ◦ ◦ • ◦ Essays & Resources Wiki Syntax Sandbox Usertools Sister Sites SCP International Wanderer's Library Create account or Sign in Getting Started Guide for Newcomers Join the Site Contribute | FAQ Universe Hub Main | Forum SCP by Series I | II | III | IV | V VI | VII | VIII | IX Other SCP Explained | Joke International Feed New Pages Shortest | Top Rated Recent Changes New Forum Posts Lowest Rated Pages Stories Tales Hub | Series Groups of Interest GoI Formats Canon Hub Discovery Artwork Hub Curated Lists Curated Tale Series Tag Search Random SCP | Tale | GOI | Art Random Page ◦ ◦ ◦ ◦ • ◦ ◦ SCP-679 rating: +187+–x Subject in the later stages of infection Item #: SCP-679 Object Class: Keter Special Containment Procedures: Samples of SCP-679 should be contained in sealed glass vials, with the temperature kept at 25 °C. Infected subjects should be kept restrained in a sterile environment. All personnel handling samples or subjects should wear class A HAZMAT suits. Any material or infected subjects removed from containment should be incinerated immediately.
To prevent potential cross contamination at no point should samples of SCP-679 and SCP-1077 be stored at the same facility.
Description: SCP-679 is a fungal infection of a previously unknown Aspergillus species.
It was discovered among the local homeless population in ███████, Florida.
It is highly infectious through direct contact with the fungus, though other means of transmission have not been ruled out.
In early stages, subjects complain of entoptic phenomena. Subjects report seeing tiny bright dots moving rapidly in their field of vision. This is especially prevalent when sneezing or looking into strong blue light.
After approximately one week from initial exposure, the sclera turns black. The subject loses vision at this time, becoming entirely blind. Within a day of this, small ulcerations appear in the corners of the eyes. This causes the vitreous humor to begin leaking out, having the appearance of thick black tears.
Mycelia are also pushed through the ulcerations. Each mycelium resembles a thin white thread coated with slime, reaching as long as twenty-five centimeters. As the ulcerations widen and more of the humor leaks out, more mycelia appear.
At this stage, the eye begins to rot entirely, a process sped up by the fungus. However, it seems to protect the rest of the eye socket and the nerve, preventing infection by other pathogens in eighty to ninety percent of test subjects. By the time the eyes have gone entirely, the sockets are filled with the fungus, with a thick mass of mycelia hanging from the empty sockets. This process takes approximately two weeks from the time the ulcerations appear.
Once the eyes are completely gone, mycelia invade the sinuses, where they trigger increased mucus production, which the fungus appears to feed upon.
At this stage, the fungus becomes mobile, the individual threads gaining motility. They move around the subject's face in seemingly random patterns.
Once the fungus begins moving on its own, subjects report their vision returning. The fungus appears to have photosensitive cells, as well as a currently poorly-understood ability to interface with the optic nerve. Subjects describe normal (and in some cases improved) eyesight, except for a much wider field of vision.
However, whenever a human with apparently normal eyes enters their field of vision, subjects experience visual hallucinations (fires, dangerous animals, sudden tilts in the floor) that seem designed to drive them in the direction of the uninfected. Once they are in range, the mycelia reach out to touch the uninfected human's eyes. This appears to be a reproductive strategy for the fungus.
Curing the condition has so far been possible only in the earliest stages of infection.
Once the sclera changes, the only treatment is surgical intervention and cauterization of all tissue in the socket and sinuses.
Additional test subjects to explore the lifecycle and reproduction of SCP-679 are requested.
« SCP-678 | SCP-679 | SCP-680 » _ccfungushallucinationketermind-affectingocularscptactilevisual page revision: 28, last edited: 10 Apr 2024 17:27 Edit Rate (+187) Tags Discuss (34) History Files Print Site tools + Options Edit Sections Append Edit Meta Watchers Backlinks Page Source Parent Lock Page Rename Delete Help  | Terms of Service  | Privacy  | Report a bug  | Flag as objectionable Powered by Wikidot.com Unless otherwise stated, the content of this page is licensed under Creative Commons Attribution-ShareAlike 3.0 License Click here to edit contents of this page.
Click here to toggle editing of individual sections of the page (if possible). Watch headings for an "edit" link when available.
Append content without editing the whole page source.
Check out how this page has evolved in the past.
If you want to discuss contents of this page - this is the easiest way to do it.
View and manage file attachments for this page.
A few useful tools to manage this Site.
See pages that link to and include this page.
Change the name (also URL address, possibly the category) of the page.
View wiki source for this page without editing.
View/set parent page (used for creating breadcrumbs and structured layout).
Notify administrators if there is objectionable content in this page.
Something does not work as expected? Find out what you can do.
General Wikidot.com documentation and help section.
Wikidot.com Terms of Service - what you can, what you should not etc.
Wikidot.com Privacy Policy.
